Cargando…
Intratumorally injected pro-inflammatory allogeneic dendritic cells as immune enhancers: a first-in-human study in unfavourable risk patients with metastatic renal cell carcinoma
BACKGROUND: Accumulating pre-clinical data indicate that the efficient induction of antigen-specific cytotoxic CD8+ T cells characterizing viral infections is caused by cross-priming where initially infected DCs produce an unique set of inflammatory factors that recruit and activate non-infected bys...
Autores principales: | Laurell, Anna, Lönnemark, Maria, Brekkan, Einar, Magnusson, Anders, Tolf, Anna, Wallgren, Anna Carin, Andersson, Bengt, Adamson, Lars, Kiessling, Rolf, Karlsson-Parra, Alex |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5477104/ https://www.ncbi.nlm.nih.gov/pubmed/28642820 http://dx.doi.org/10.1186/s40425-017-0255-0 |
Ejemplares similares
-
Long-term survival in unfavourable-risk mRCC patients after intratumoral administration of a cell-based allogeneic vaccine
por: Karlsson-Parra, Alex, et al.
Publicado: (2015) -
Allogeneic lymphocyte-licensed DCs expand T cells with improved antitumor activity and resistance to oxidative stress and immunosuppressive factors
por: Jin, Chuan, et al.
Publicado: (2014) -
Ilixadencel – an Allogeneic Cell-Based Anticancer Immune Primer for Intratumoral Administration
por: Karlsson-Parra, Alex, et al.
Publicado: (2018) -
Phase I trial evaluating safety and efficacy of intratumorally administered inflammatory allogeneic dendritic cells (ilixadencel) in advanced gastrointestinal stromal tumors
por: Fröbom, Robin, et al.
Publicado: (2020) -
Intratumoral administration of pro-inflammatory allogeneic dendritic cells improved the anti-tumor response of systemic anti-CTLA-4 treatment via unleashing a T cell-dependent response
por: Jin, Chuan, et al.
Publicado: (2022)